Advertisement

Management of Humoral Primary Immunodeficiencies in Adults

  • Gianfranco Vitiello
  • Giacomo Emmi
  • Boaz Palterer
Chapter
Part of the Rare Diseases of the Immune System book series (RDIS)

Abstract

Immunoglobulin replacement therapy is the cornerstone for the management of humoral primary immunodeficiencies as its major goal is the minimization of infective complications. Clinical phenotype and the presence of complications should guide the dosage of immunoglobulin replacement therapy and the choice between intravenous (IVIg) and subcutaneous (SCIg) route of administration. Mild infusion reactions are common with IVIg, whereas local pain, swelling, and erythema represent the major complaints with SCIg. Severe adverse reactions are rare and mainly associated to high-dose IVIg and comprise anaphylaxis, aseptic meningitis, and thrombosis.

Antibiotic prophylaxis is sometimes used in these patients, but standard protocols are still lacking. As unusual microorganisms and antibiotic resistance are common, an antibiogram should be obtained before initiating an empiric therapy.

Keywords

Immunoglobulin replacement therapy Intravenous immunoglobulin Subcutaneous immunoglobulin Antibiotic prophylaxis Hematopoietic stem cell transplantation 

References

  1. 1.
    von Behring E, Kitasato S. The mechanism of diphtheria immunity and tetanus immunity in animals. 1890. Mol Immunol. 1991;28(1317):1319–20.Google Scholar
  2. 2.
    Lindenmann J. Origin of the terms “antibody” and “antigen”. Scand J Immunol. 1984;19:281–5.CrossRefGoogle Scholar
  3. 3.
    Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth JN, Melin M, Taylor HL. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids 1a,b,c,d. J Am Chem Soc. 1946;68:459–75.CrossRefGoogle Scholar
  4. 4.
    Bruton OC. Agammaglobulinemia Pediatrics. 1952;9:722–8.PubMedGoogle Scholar
  5. 5.
    Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. Vox Sang. 1962;7:157–74.CrossRefGoogle Scholar
  6. 6.
    Lieberman P, Berger M. Intramuscular versus intravenous immunoglobulin replacement therapy and measurement of immunoglobulin levels during immunoglobulin replacement therapy. J Allergy Clin Immunol Pract. 2013;1:705–6.CrossRefGoogle Scholar
  7. 7.
    Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injection. Lancet. 1972;1:1208–12.CrossRefGoogle Scholar
  8. 8.
    Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98:12–28.CrossRefGoogle Scholar
  9. 9.
    Ashida ER, Saxon A. Home intravenous immunoglobulin therapy by self-administration. J Clin Immunol. 1986;6:306–9.CrossRefGoogle Scholar
  10. 10.
    Afonso AFB, João CMP. The production processes and biological effects of intravenous immunoglobulin. Biomol Ther. 2016;6:1–20.Google Scholar
  11. 11.
    Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2014;136:1–20e78.Google Scholar
  12. 12.
    Torgerson TR. Overview of routes of IgG administration. J Clin Immunol. 2013;33:2012–4.Google Scholar
  13. 13.
    Sriaroon P, Ballow M. Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Immunol Allergy Clin N Am. 2015;35:713–30.CrossRefGoogle Scholar
  14. 14.
    Younger MEM, Blouin W, Duff C, Epland KB, Murphy E, Sedlak D. Subcutaneous immunoglobulin replacement therapy: Ensuring success. J Infus Nurs. 2015;38:70–9.CrossRefGoogle Scholar
  15. 15.
    Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: From subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32:1153–64.CrossRefGoogle Scholar
  16. 16.
    Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4:427–40.CrossRefGoogle Scholar
  17. 17.
    Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139:S1–S46.CrossRefGoogle Scholar
  18. 18.
    Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017;188:333–41.CrossRefGoogle Scholar
  19. 19.
    Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: Results from a multicenter prospective cohort study. J Clin Immunol. 2011;31:315–22.CrossRefGoogle Scholar
  20. 20.
    Wolf HM, Thon V, Litzman J, Eibl MM. Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients. Front Immunol. 2015;6:32.  https://doi.org/10.3389/fimmu.2015.00032.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Björkander J, Hammarström L, Smith CI, Buckley RH, Cunningham-Rundles C, Hanson LA. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol. 1987;7:8–15.CrossRefGoogle Scholar
  22. 22.
    Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: An evidence-based review. Drugs. 2013;73:1307–19.CrossRefGoogle Scholar
  23. 23.
    Shabaninejad H, Asgharzadeh A, Rezaei N, Rezapoor A. A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis. Expert Rev Clin Immunol. 2016;12:595–602.CrossRefGoogle Scholar
  24. 24.
    Peter JG, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy. 2014;6:853–69.CrossRefGoogle Scholar
  25. 25.
    Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.CrossRefGoogle Scholar
  26. 26.
    Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525–53.CrossRefGoogle Scholar
  27. 27.
    Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125:1354–1360.e4.CrossRefGoogle Scholar
  28. 28.
    Bonagura VR. Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease. Ann Allergy Asthma Immunol. 2013;111:S10–3.CrossRefGoogle Scholar
  29. 29.
    Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med. 1986;314:560–4.CrossRefGoogle Scholar
  30. 30.
    Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol. 2012;129:628–34.CrossRefGoogle Scholar
  31. 31.
    Sundin U, Nava S, Hammarström L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol. 1998;112:341–6.CrossRefGoogle Scholar
  32. 32.
    Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259.CrossRefGoogle Scholar
  33. 33.
    Kaarthigeyan K, Burli VV. Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency. J Pediatr Neurosci. 2011;6:160–1.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Jarius S, Eichhorn P, Albert MH, Wagenpfeil S, Wick M, Belohradsky BH, Hohlfeld R, Jenne DE, Voltz R. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. Blood. 2007;109:4376–82.CrossRefGoogle Scholar
  35. 35.
    Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol. 2009;256:339–42.CrossRefGoogle Scholar
  36. 36.
    Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16:313–8.CrossRefGoogle Scholar
  37. 37.
    Barada W, Muwakkit S, Hourani R, Bitar M, Mikati M. Cerebral sinus thrombosis in a patient with humoral immunodeficiency on intravenous immunoglobulin therapy: a case report. Neuropediatrics. 2008;39:131–3.CrossRefGoogle Scholar
  38. 38.
    Iroh Tam P-Y, Richardson M, Grewal S. Fatal case of bilateral internal jugular vein thrombosis following IVIg infusion in an adolescent girl treated for ITP. Am J Hematol. 2008;83:323–5.CrossRefGoogle Scholar
  39. 39.
    Funk MB, Gross N, Gross S, Hunfeld A, Lohmann A, Guenay S, Hanschmann KM, Keller-Stanislawski B. Thromboembolic events associated with immunoglobulin treatment. Vox Sang. 2013;105:54–64.CrossRefGoogle Scholar
  40. 40.
    Huang L, Kanellis J, Mulley W. Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection. Nephrology (Carlton). 2011;16:239–42.CrossRefGoogle Scholar
  41. 41.
    Okuda D, Flaster M, Frey J, Sivakumar K. Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology. 2003;60:1825–6.CrossRefGoogle Scholar
  42. 42.
    Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008;48:1598–601.CrossRefGoogle Scholar
  43. 43.
    Gerber S, Gaida A, Spiegl N, Wymann S, Antunes AM, El MI, Zurbriggen B, Hubsch A, Imboden M. Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood Group A- and B-specific immunoaffinity chromatography: industry-scale assessment. BioDrugs. 2016;30:441–51.CrossRefGoogle Scholar
  44. 44.
    Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med. 1992;326:270–1.CrossRefGoogle Scholar
  45. 45.
    von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon H-U. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood. 2006;108:4255–9.CrossRefGoogle Scholar
  46. 46.
    Ibrahim J, Al Amri A, Ghatasheh G. Transfusion-related acute lung injury after immunoglobulin infusion for Kawasaki disease: a case report and literature review. Glob Pediatr Heal. 2017;4:2333794X17746545.Google Scholar
  47. 47.
    Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol. 1991;36:83–6.PubMedGoogle Scholar
  48. 48.
    Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy—United States 1985-1998. MMWR Morb Mortal Wkly Rep. 1999;48:518–21.Google Scholar
  49. 49.
    Dantal J. Intravenous Immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013;38:275–84.CrossRefGoogle Scholar
  50. 50.
    Nguyen MK, Rastogi A, Kurtz I. True hyponatremia secondary to intravenous immunoglobulin. Clin Exp Nephrol. 2006;10:124–6.CrossRefGoogle Scholar
  51. 51.
    Lawn N, Wijdicks EFM, Burritt MF. Intravenous immune globulin and pseudohyponatremia. N Engl J Med. 1998;339:632.CrossRefGoogle Scholar
  52. 52.
    Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–16.CrossRefGoogle Scholar
  53. 53.
    Krivan G, Jolles S, Granados EL, Paolantonacci P, Ouaja R, Cissé OA, Bernatowska E. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017;6:76–83.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol. 2001;101:284–8.CrossRefGoogle Scholar
  55. 55.
    Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol. 2002;118:1187–9.CrossRefGoogle Scholar
  56. 56.
    Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev. 2008;22:58–69.CrossRefGoogle Scholar
  57. 57.
    Ziegner UHM, Kobayashi RH, Cunningham-Rundles C, et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol. 2002;102:19–24.CrossRefGoogle Scholar
  58. 58.
    Tarzi MD, Grigoriadou S, Carr SB, Kuitert LM, Longhurst HJ. Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol. 2009;155:147–55.CrossRefGoogle Scholar
  59. 59.
    Kainulainen L, Nikoskelainen J, Vuorinen T, Tevola K, Liippo K, Ruuskanen O. Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med. 1999;159:1199–204.CrossRefGoogle Scholar
  60. 60.
    Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1:573–82.CrossRefGoogle Scholar
  61. 61.
    Steel HC, Theron AJ, Cockeran R, Anderson R, Feldman C. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediat Inflamm. 2012;2012:584262.CrossRefGoogle Scholar
  62. 62.
    Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987;19:831–8.CrossRefGoogle Scholar
  63. 63.
    Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121:55–63.CrossRefGoogle Scholar
  64. 64.
    Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11:425–34.CrossRefGoogle Scholar
  65. 65.
    Sperlich JM, Grimbacher B, Workman S, Haque T, Seneviratne SL, Burns SO, Reiser V, Vach W, Hurst JR, Lowe DM. Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency. J Allergy Clin Immunol Pract. 2018;6:159–168.e3.CrossRefGoogle Scholar
  66. 66.
    Uzzan M, Ko HM, Mehandru S, Cunningham-Rundles C. Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). Curr Gastroenterol Rep. 2016;18:17.CrossRefGoogle Scholar
  67. 67.
    Woodward J, Gkrania-Klotsas E, Kumararatne D. Chronic norovirus infection and common variable immunodeficiency. Clin Exp Immunol. 2017;188:363–70.CrossRefGoogle Scholar
  68. 68.
    Brachet-Castang C, Viallard JF, Fourche J, Le Flèche A, Grimont PA, Pellegrin JL, Maugein J. Bactériémie à Flexispira rappini et déficit immunitaire commun variable. Médecine Mal Infect. 2005;35:95–7.CrossRefGoogle Scholar
  69. 69.
    Radanović I, Rkman D, Zekan P, Kutleša M, Baršić B. Chronic meningoencephalitis caused by Echo virus 6 in a patient with common variable immunodeficiency. Wien Klin Wochenschr. 2018;130:70–2.CrossRefGoogle Scholar
  70. 70.
    Bradley J, Moran F, Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev. 2002;3:CD002166.Google Scholar
  71. 71.
    Wehr C, Gennery AR, Lindemans C, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. 2015;135:988–97e6.CrossRefGoogle Scholar
  72. 72.
    Kostel Bal S, Haskologlu S, Serwas NK, et al. Multiple presentations of LRBA deficiency: a single-center experience. J Clin Immunol. 2017;37:790–800.CrossRefGoogle Scholar
  73. 73.
    Hsu AP, West RR, Calvo KR, Cuellar-Rodriguez J, Parta M, Kelly SJ, Ganson NJ, Hershfield MS, Holland SM, Hickstein DD. Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: successful hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2016;138:628–630.e2.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gianfranco Vitiello
    • 1
  • Giacomo Emmi
    • 1
  • Boaz Palterer
    • 1
  1. 1.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly

Personalised recommendations